Skip to content

Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial

Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: A Multicenter, Randomized, Double-blind, Controlled Clinical Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06569953
Enrollment
284
Registered
2024-08-26
Start date
2024-08-26
Completion date
2025-08-31
Last updated
2025-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pain, Chronic Pain, Postoperative Pain

Brief summary

The goal of this clinical trial is to evaluate the efficacy and safety of liposomal Bupivacaine administered by paravertebral block for the treatment of acute and chronic pain after video-assisted thoracoscopic lobectomy.

Detailed description

Researchers will compare liposomal bupivacaine to bupivacaine to see if liposomal bupivacaine works better to treat acute and chronic pain after video-assisted thoracoscopic lobectomy.Participants will:1.Received liposomal bupivacaine or bupivacaine paravertebral block before surgery. 2.Keep a diary of their pain scores within 30min after recovery from anesthesia and 6h, 12h, 24h, 48h, 72h and 90d after the beginning of injection of experimental drugs.

Interventions

DRUGLiposomal bupivacaine

Participants randomized to the intervention arm received 266 mg of liposomal bupivacaine for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline).

DRUGBupivacaine Hydrochloride

Participants randomized to the intervention arm received 0.5% 100 mg of bupivacaine hydrochloride for paravertebral block before surgery.(The volume was expanded to 30 mL with normal saline)

Sponsors

People's Hospital of Chongqing
CollaboratorOTHER
LanZhou University
CollaboratorOTHER
Xiangya Hospital of Central South University
CollaboratorOTHER
Shapingba District People's Hospital of Chongqing
CollaboratorUNKNOWN
The Second Affiliated Hospital of Chongqing Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

Randomization was performed in a 1:1 ratio with the use of block randomization.SAS software (version 9.4 or higher) was used to generate the random number and the treatment group to which the random number was assigned.Assignment of Randomization Numbers Using the Interactive Web Response System (IWRS).

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Participants who scheduled for elective video-assisted thoracoscopic lobectomy under general anesthesia. * Participants were 18 years or older. * 18 kg/m2≤BMI≤30 kg/m2 * Participants with American Society of Anesthesiology (ASA) physical status I-III. * Understand the significance, possible benefits, potential risks of the trial in detail.Understand the procedures and methods of this study.Willing to complete the trial in strict compliance with the clinical trial protocol.Sign the informed consent form voluntarily.

Exclusion criteria

* with severe cardiovascular and cerebrovascular diseases such as myocardial infarction,unstable angina pectoris,severe cardiac rhythm disorders (second- and third-degree heart block,etc.), New York Heart Association (NYHA) functional class III/IV,Ischemic stroke. * with psychiatric disorders (such as schizophrenia,depression,etc.) and cognitive impairment. * with sensory disorders such as hyperalgesia. * with other bodily pain. * allergy to amide-type local anesthetics or any of the trial drugs * taking drugs that affect liver metabolism,corticosteroids,benzodiazepines,non-steroidal anti-inflammatory drugs(NSAIDs),opioid agonist-antagonist,central-alpha 2-agonists,anticonvulsants,antidepressants within 72h. * with a history of alcohol or opioid abuse. * who were pregnant or lactating. * who were currently included in another clinical study within 3 months.

Design outcomes

Primary

MeasureTime frameDescription
Area under the movement-evoked pain intensity-time curvefrom 0-72 hours after the interventionArea under the pain intensity-time curve in the movement (or coughing) state within 72h after the intervention.
The incidence of chronic postoperative painpostoperative day (POD) 90The incidence of chronic postoperative pain at 90 days

Secondary

MeasureTime frameDescription
Pain score at rest30 minutes after recovery from anesthesia,6 hours,12hours, 24hours , 48hours and 72 hours after the interventionUse pain Numeric Rating Scale(NRS) to evaluate the pain score at rest at 30minutes after recovery from anesthesia and at 6 hours, 12hours, 24hours , 48hours and 72 hours after the intervention.(NRS scale 0-10, where 0 was no pain, and 10 was the worst possible pain)
Proportion of participants who did not use rescue analgesiafrom 0-72 hours after the interventionProportion of participants who did not use rescue analgesia during 0-12 hours, 12-24 hours, 24-48 hours, 48-72 hours and 0-72 hours after the intervention.
The cumulative dosage of rescue analgesiafrom 0-72 hours after the interventionThe cumulative dosage of rescue analgesia during 0-12 hours, 12-24 hours, 24-48 hours, 48-72hours and 0-72hours after the intervention.
The time of first use of rescue analgesiafrom 0-72 hours after the interventionThe time of first use of rescue analgesia
Area under the rest pain intensity-time curvefrom 0-72 hours after the interventionArea under the pain intensity-time curve at rest within 72h after the intervention.
Length of hospital stayFrom date of surgery until the date of first hospital discharge,assessed up to 1 monthsDuration of participants from hospital admission to hospital discharge
Chronic pain scorepostoperative day (POD) 90Use pain Numeric Rating Scale(NRS) to evaluate the movement-evoked pain score and rest pain score at 90 days after surgery.(NRS scale 0-10, where 0 was no pain, and 10 was the worst possible pain)
Score of satisfaction with analgesiaAt 72 hours after the interventionAt 72 hours after the intervention,the participants rated the satisfaction with analgesia.Satisfaction rating scale 0-5,where 0 was poor drug effectiveness, and 5 was excellent drug efficacy)
First time out-of-bedFrom date of surgery until the date of first out-of-bed,assessed up to 7 daysTime of participant's first out-of-bed activity after surgery
Movement-evoked pain score30 minutes after recovery from anesthesia,6 hours, 12hours, 24hours , 48hours and 72 hours after the interventionUse pain Numeric Rating Scale(NRS) to evaluate the movement-evoked pain score at 30minutes after recovery from anesthesia and at 6 hours, 12hours, 24hours , 48hours and 72 hours after the intervention.(NRS scale 0-10, where 0 was no pain, and 10 was the worst possible pain)

Countries

China

Contacts

Primary ContactHe Huang, ph.D
huanghe@cqmu.edu.cn86+13708385559
Backup ContactGuangyou Duan, ph.D
duangy@hospital.cqmu.edu.cn86+18323376014

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026